ReviewFrontiers in immunology2023
Precision-engineering of subunit vaccine particles for prevention of infectious diseases.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Synthetic Ligands of Myeloid C-Type Lectin Receptors.Chembiochem : a European journal of chemical biology · 2026Review
- A self-assembled protein nanocage as a universal influenza vaccine induces enhanced broadly cross-reactive immunity.Biomaterials · 2026Article
- Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential.MedComm · 2025Review
- The potential and challenges of circular RNA in the development of vaccines and drugs for emerging infectious diseases.Molecular therapy. Nucleic acids · 2025Review
- Bivalent Oral Vaccine Using AttenuatedVaccines · 2025Article
- Preparation and Immunogenicity Evaluation of a Ferritin-Based GnRH Nanoparticle Vaccine.Vaccines · 2025Article
- Recombinant Tetrameric Neuraminidase Subunit Vaccine Provides Protection Against Swine Influenza A Virus Infection in Pigs.Vaccines · 2025Article
- Advances in neoantigen-based immunotherapy for head and neck squamous cell carcinoma: a comprehensive review.Frontiers in oncology · 2025Review
- Intranasal Epitope-Polymer Vaccine Lodges Resident Memory T Cells Protecting Against Influenza Virus.Advanced healthcare materials · 2024Article
- Introduction of protein vaccine candidate based on AP65, AP33, and α-actinin proteins against Trichomonas vaginalis parasite: an immunoinformatics design.Parasites & vectors · 2024Article
- A universal design of restructured dimer antigens: Development of a superior vaccine against the paramyxovirus in transgenic rice.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- A novel oral vaccine delivery system for enhancing stability and immune protection: bacterium-like particle with functional coating.Frontiers in microbiology · 2024Article
- Role of canonical and noncanonical autophagy pathways in shaping the life journey of B cells.Frontiers in immunology · 2024Review
- Changes in intestinal flora of mice induced by rEg.P29 epitope peptide vaccines.Immunity, inflammation and disease · 2023Article
- Q fever immunology: the quest for a safe and effective vaccine.NPJ vaccines · 2023Review
- Polymeric epitope-based vaccine induces protective immunity against group A Streptococcus.NPJ vaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines remain the best approach for the prevention of infectious diseases. Protein subunit vaccines are safe compared to live-attenuated whole cell vaccines but often show reduced immunogenicity. Subunit vaccines in particulate format show improved vaccine efficacy by inducing strong immune responses leading to protective immunity against the respective pathogens. Antigens with proper conformation and function are often required to induce functional immune responses. Production of such antigens requiring post-translational modifications and/or composed of multiple complex domains in bacterial hosts remains challenging. Here, we discuss strategies to overcome these limitations toward the development of particulate vaccines eliciting desired humoral and cellular immune responses. We also describe innovative concepts of assembling particulate vaccine candidates with complex antigens bearing multiple post-translational modifications. The approaches include non-covalent attachments (e.g. biotin-avidin affinity) and covalent attachments (e.g. SpyCatcher-SpyTag) to attach post-translationally modified antigens to particles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.